Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy
Authors
Keywords
-
Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 64, Issue 11, Pages 7507-7532
Publisher
American Chemical Society (ACS)
Online
2021-05-29
DOI
10.1021/acs.jmedchem.1c00179
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade
- (2020) Liangliang Wang et al. Science Translational Medicine
- Combination of sunitinib and PD-L1 blockade enhances anticancer efficacy of TLR7/8 agonist-based nanovaccine
- (2019) Hyunjoon Kim et al. MOLECULAR PHARMACEUTICS
- Efficacy of TLR7 agonistic imidazoquinoline as immunochemotherapeutic agent against P. Berghei ANKA infected rodent host
- (2019) Ruchika Saroa et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Niosomes as efficient drug delivery modules for encapsulation of Toll-like receptor 7 agonists and IDO-inhibitor
- (2019) Jyoti Rathee et al. APPLIED SURFACE SCIENCE
- TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy
- (2018) Lan Huang et al. Cellular & Molecular Immunology
- A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
- (2018) Kevin C. Barry et al. NATURE MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
- (2018) Mirjana Efremova et al. Nature Communications
- TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy
- (2018) Christopher B. Rodell et al. Nature Biomedical Engineering
- Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti–PD-L1 to eliminate melanoma in mice
- (2018) Ying Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
- (2018) Antoni Ribas et al. Cancer Discovery
- Nanoparticle-Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses
- (2018) Lutz Nuhn et al. ADVANCED MATERIALS
- Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
- (2018) Christopher S. Garris et al. IMMUNITY
- Trends in the global immuno-oncology landscape
- (2018) Jun Tang et al. NATURE REVIEWS DRUG DISCOVERY
- Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy
- (2017) P. S. Chowdhury et al. JOURNAL OF INTERNAL MEDICINE
- Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines
- (2017) Mallesh Beesu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Photochromic Hydrazone Switches with Extremely Long Thermal Half-Lives
- (2017) Hai Qian et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- TLR7 Structure: Cut in Z-Loop
- (2016) Kazuhiko Maeda et al. IMMUNITY
- Discovery of 6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma
- (2016) Keith Biggadike et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus
- (2016) David McGowan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide
- (2016) Alex Cortez et al. JOURNAL OF MEDICINAL CHEMISTRY
- Human Toll-like Receptor (TLR) 8-Specific Agonistic Activity in Substituted Pyrimidine-2,4-diamines
- (2016) Mallesh Beesu et al. JOURNAL OF MEDICINAL CHEMISTRY
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Big opportunities for small molecules in immuno-oncology
- (2015) Jerry L. Adams et al. NATURE REVIEWS DRUG DISCOVERY
- Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted Pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors
- (2014) Oussama Dehbi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Structure and function of toll-like receptor 8
- (2014) Umeharu Ohto et al. MICROBES AND INFECTION
- A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: Comparison of hERG binding and target residence time with PF-3893787
- (2013) Mounir Andaloussi et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- TLR agonists: our best frenemy in cancer immunotherapy
- (2013) Sabina Kaczanowska et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Identification and Optimization of Pteridinone Toll-like Receptor 7 (TLR7) Agonists for the Oral Treatment of Viral Hepatitis
- (2013) Paul A. Roethle et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural Reorganization of the Toll-Like Receptor 8 Dimer Induced by Agonistic Ligands
- (2013) H. Tanji et al. SCIENCE
- Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice
- (2011) Sally M. Amos et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- TLR8 Activates HIV from Latently Infected Cells of Myeloid-Monocytic Origin Directly via the MAPK Pathway and from Latently Infected CD4 + T Cells Indirectly via TNF-α
- (2011) Erika Schlaepfer et al. JOURNAL OF IMMUNOLOGY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Evaluation of a 12-color flow cytometry panel to study lymphocyte, monocyte, and dendritic cell subsets in humans
- (2010) Patrick Autissier et al. CYTOMETRY PART A
- Structure−Activity Relationships in Human Toll-Like Receptor 7-Active Imidazoquinoline Analogues
- (2010) Nikunj M. Shukla et al. JOURNAL OF MEDICINAL CHEMISTRY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands
- (2009) Angela Meier et al. AIDS
- Type I Interferon Modulates Monocyte Recruitment and Maturation in Chronic Inflammation
- (2009) Pui Y. Lee et al. AMERICAN JOURNAL OF PATHOLOGY
- Comparison of Nine Programs Predicting pKaValues of Pharmaceutical Substances
- (2009) Chenzhong Liao et al. Journal of Chemical Information and Modeling
- A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia
- (2009) D E Spaner et al. LEUKEMIA
- Homology modeling of human Toll-like receptors TLR7, 8, and 9 ligand-binding domains
- (2009) Tiandi Wei et al. PROTEIN SCIENCE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started